Abstracts tagged "Henoch-Schönlein purpura and risk assessment"

Abstract Number: 895 • 2015 ACR/ARHP Annual Meeting
Relapses and Predictive Factors in Henoch-SchÖnlein Purpura. study of 417 Patients
Natalia Palmou¹, Vanesa Calvo-Río¹, Javier Loricera¹, Enar Pons², Patricia Fuentevilla³, Jose L. Hernández⁴, Cristina Mata-Arnaiz⁵, L. Martín⁶, Francisco Ortiz-Sanjuán¹, L Alvarez⁷, Carmen Gonzalez-Vela⁸, Domingo González-Lamuño⁹, Hector Fernandez-Llaca¹⁰, MA González López¹¹, S. Armesto¹⁰, M Arias¹², Miguel Angel Gonzalez-Gay¹ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²RHEUMATOLOGY, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, SANTANDER, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, santander, Spain, ⁴Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁵Rheumatology, Hospital Laredo, Santander, Spain, ⁶Nephrology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ⁷PEDIATRIC, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, SANTANDER, Spain, ⁸Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁹Pediatrics, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ¹⁰Dermatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ¹¹Dermatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, santander, Spain, ¹²nephrology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, santander, Spain
Background/Purpose: Although the prognosis of Henoch-Schönlein purpura (HSP) is usually favorable, relapses are relatively frequent.Objectives: Our aim was to analyze the frequency, type and risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].